Synthetic vaccine particles immune tolerance mechanism published in Nature Nanotechnology

(The Yates Network) Preclinical studies show that Selecta Biosciences' proprietary immune therapies use a targeted mechanism of action to improve the efficacy and safety of biologic therapeutics and to address autoimmune diseases and allergies. The company is developing targeted antigen-specific immune therapies for rare and serious diseases. The data in Nature Nanotechnology support Selecta's lead clinical program, showing Selecta's SVP-Rapamycin induces antigen-specific immune tolerance and pr